{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:09:37Z","timestamp":1781629777524,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG22089"],"award-info":[{"award-number":["IG22089"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The standard treatment for young patients with untreated PTCLs is based on anthracycline containing-regimens followed by high-dose-chemotherapy and stem-cell-transplantation (HDT\u2009+\u2009SCT), but only 40% of them can be cured. Romidepsin, a histone-deacetylase inhibitor, showed promising activity in relapsed PTCLs; in first line, Romidepsin was added with CHOP. We designed a study combining romidepsin and CHOEP as induction before HDT\u2009+\u2009auto-SCT in untreated PTCLs (PTCL-NOS, AITL\/THF, ALK-ALCL), aged 18\u201365 years. A phase Ib\/II trial was conducted to define the maximum tolerated dose (MTD) of Ro-CHOEP, and to assess efficacy and safety of 6 Ro-CHOEP as induction before HDT. The study hypothesis was to achieve a 18-month PFS of 70%. Twenty-one patients were enrolled into phase Ib; 7 dose-limiting toxicities were observed, that led to define the MTD at 14\u2009mg\/ms. Eighty-six patients were included in the\u00a0phase II. At a median follow-up of 28 months, the 18-month PFS was 46.2% (95%CI:35.0\u201356.7), and the 18-month overall survival was 73.1% (95%CI:61.6\u201381.7). The overall response after induction was 71%, with 62% CRs. No unexpected toxicities were reported. The primary endpoint was not met; therefore, the enrollment was stopped at a planned interim analysis. The addition of romidepsin to CHOEP did not improve the PFS of untreated PTCL patients.<\/jats:p>","DOI":"10.1038\/s41375-022-01780-1","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T14:03:14Z","timestamp":1674050594000},"page":"433-440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib\/II study"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2977-0098","authenticated-orcid":false,"given":"Annalisa","family":"Chiappella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dodero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorella","family":"Orsucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Veronica","family":"Usai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Castellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Stefoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9425-9026","authenticated-orcid":false,"given":"Antonio","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Zanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Ciancia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ghiggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Gaia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5337-5947","authenticated-orcid":false,"given":"Annalisa","family":"Arcari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella","family":"Ilariucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio Ruggero","family":"Zilioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Flenghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melania","family":"Celli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Volpetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Ballerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Musuraca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Bruna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Patti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9504-991X","authenticated-orcid":false,"given":"Luca","family":"Arcaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Magagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2047-1099","authenticated-orcid":false,"given":"Federica","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisa","family":"Bermema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3052-7463","authenticated-orcid":false,"given":"Alessandra","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Boccomini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovannino","family":"Ciccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Carniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano Aldo","family":"Pileri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-1353","authenticated-orcid":false,"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"1780_CR1","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. WHO classification of tumours, Revised 4th Edition, 2. IARC, Lyon, France, 2017."},{"key":"1780_CR2","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood.2021015114","volume":"140","author":"M Brink","year":"2022","unstructured":"Brink M, Meeuwes FO, Van der Poel MWM, Kersten MJ, Wondergem M, Mutsaers PGNJ, et al. Impact of etoposide and ASCT on survival among patients aged < 65 years with stage II to IV PTCL: a population-based cohort study. Blood. 2022;140:1009\u201319.","journal-title":"Blood."},{"key":"1780_CR3","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","volume":"123","author":"AJ Moskowitz","year":"2014","unstructured":"Moskowitz AJ, Lunning MA, Horwitz SM. How I treat the peripheral T-cell lymphomas. Blood. 2014;123:2636\u201344.","journal-title":"Blood."},{"key":"1780_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/bjh.14473","volume":"176","author":"N Schmitz","year":"2017","unstructured":"Schmitz N, De Leval L. How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future. Br J Haematol. 2017;176:851\u201366.","journal-title":"Br J Haematol"},{"key":"1780_CR5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","volume":"27","author":"P Reimer","year":"2009","unstructured":"Reimer P, Rudiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27:106\u201313.","journal-title":"J Clin Oncol"},{"key":"1780_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","volume":"79","author":"J Rodriguez","year":"2007","unstructured":"Rodriguez J, Conde E, Gutierrez A, Arranz R, Le\u00f3n A, Mar\u00edn J, et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol. 2007;79:32\u201338.","journal-title":"Eur J Haematol"},{"key":"1780_CR7","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F D\u2019Amore","year":"2012","unstructured":"D\u2019Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093\u20139.","journal-title":"J Clin Oncol"},{"key":"1780_CR8","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1038\/leu.2014.79","volume":"28","author":"P Corradini","year":"2014","unstructured":"Corradini P, Vitolo U, Rambaldi A, Miceli R, Patriarca F, Gallamini A, et al. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia. 2014;28:1885\u201391.","journal-title":"Leukemia."},{"key":"1780_CR9","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","volume":"25","author":"JS Abramson","year":"2014","unstructured":"Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014;25:2211\u20137.","journal-title":"Ann Oncol"},{"key":"1780_CR10","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00277-018-3288-7","volume":"97","author":"S Rohlfing","year":"2018","unstructured":"Rohlfing S, Dietrich S, Witzens-Harig M, Hegenbart U, Sch\u00f6nland S, Luft T, et al. The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience. Ann Hematol. 2018;97:1241\u201350.","journal-title":"Ann Hematol"},{"key":"1780_CR11","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631\u20136.","journal-title":"J Clin Oncol"},{"key":"1780_CR12","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","volume":"117","author":"RL Piekarz","year":"2011","unstructured":"Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117:5827\u201334.","journal-title":"Blood."},{"key":"1780_CR13","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/S2352-3026(15)00023-X","volume":"2","author":"J Dupuis","year":"2015","unstructured":"Dupuis J, Morschhauser F, Ghesquieres H, Tilly H, Casasnovas O, Thieblemont C, et al. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomized, phase Ib\/2 study. Lancet Haematol. 2015;2:e160\u2013165.","journal-title":"Lancet Haematol"},{"key":"1780_CR14","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.21.01815","volume":"40","author":"E Bachy","year":"2022","unstructured":"Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas RO, Ysebaert L, et al. Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA). J Clin Oncol. 2022;40:242\u201351.","journal-title":"J Clin Oncol"},{"key":"1780_CR15","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"1780_CR16","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","volume":"22","author":"P Corradini","year":"2004","unstructured":"Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin\u2019s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol. 2004;22:2172\u20136.","journal-title":"J Clin Oncol"},{"key":"1780_CR17","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1002\/sim.920","volume":"20","author":"S Zohar","year":"2001","unstructured":"Zohar S, Chevret S. The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies. Stat Med. 2001;20:2827\u201343.","journal-title":"Stat Med"},{"key":"1780_CR18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/sj.bjc.6602969","volume":"94","author":"J O\u2019Quigley","year":"2006","unstructured":"O\u2019Quigley J, Zohar S. Experimental designs for phase I and phase I\/II dose-finding studies. Br J Cancer. 2006;94:609\u201313.","journal-title":"Br J Cancer"},{"key":"1780_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0169-2607(02)00120-7","volume":"72","author":"S Zohar","year":"2003","unstructured":"Zohar S, Latouche A, Taconnet M, Chevret S. Software to compute and conduct sequential Bayesian phase I or II dose-ranging clinical trials with stopping rules. Comput Methods Prog Biomed. 2003;72:117\u201325.","journal-title":"Comput Methods Prog Biomed"},{"key":"1780_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-3-6","volume":"3","author":"LD Case","year":"2003","unstructured":"Case LD, Morgan TM. Design of Phase II cancer trials evaluating survival probabilities. BMC Med Res Methodol. 2003;3:6.","journal-title":"BMC Med Res Methodol"},{"key":"1780_CR21","doi-asserted-by":"crossref","unstructured":"Machin D, Campbell MJ, Tan SB, Tan SH. Sample Size Tables for Clinical Studies, 3rd edn. 2008.","DOI":"10.1002\/9781444300710"},{"key":"1780_CR22","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","volume":"27","author":"C Kyriakou","year":"2009","unstructured":"Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau JL, Kolb HJ, et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2009;27:3951\u20138.","journal-title":"J Clin Oncol"},{"key":"1780_CR23","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2011.240","volume":"26","author":"A Dodero","year":"2012","unstructured":"Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F, et al. Allogeneic transplantation following a reduced intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia. 2012;26:520\u20136.","journal-title":"Leukemia."},{"key":"1780_CR24","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1182\/bloodadvances.2021005899","volume":"6","author":"M Hamadani","year":"2022","unstructured":"Hamadani M, Ngoya M, Sureda A, Bashir Q, Litovich CA, Finel H, et al. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. Blood Adv. 2022;6:920\u201330.","journal-title":"Blood Adv"},{"key":"1780_CR25","first-page":"2646","volume":"137","author":"N Schmitz","year":"2021","unstructured":"Schmitz N, Truemper L, Bouabdallah K, Ziepert M, Leclerc M, Cartrom G, et al. A randomized phase three trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood. 2021;137:2646\u201356.","journal-title":"Blood."},{"key":"1780_CR26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393:229\u201340.","journal-title":"Lancet."},{"key":"1780_CR27","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1182\/blood.2020009004","volume":"137","author":"L Falchi","year":"2021","unstructured":"Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2021;137:2161\u201370.","journal-title":"Blood."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01780-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01780-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01780-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T11:12:17Z","timestamp":1675422737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01780-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1780"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01780-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]},"assertion":[{"value":"25 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AC - Advisory boards: Celgene-BMS, Clinigen, Gilead-Sciences, Ideogen, Janssen, Roche, SecuraBIO, Takeda. Honoraria for lectures: Astrazeneca, Celgene-BMS, Clinigen, Gilead-Sciences, Incyte, Janssen, Novartis, Roche, Takeda. AP: Honoraria from BRISTOL-Myers Squibb, F. Hoffmann-LaRoche, Helssin Healthcare, Janssen, Celgene, Gilead Sciences, Incyte, Servier, Merck Sharp & Dohme and Takeda; VRZ - Honoraria from: Takeda, Janssen, Roche. GM - Janssen Honoraria, Consultant, Incyte: Honoraria, Consultant, Roche Honoraria, Consultant, Abbvie Honoraria, Consultant. LA - Consulting or Advisory Role: Gilead Sciences, Verastem, Eusa Pharma, Incyte and ADC Therapeutics Speakers\u2019 Bureau: EUSA Pharma, Novartis Research Funding: Gilead Sciences Travel, Accommodations, Expenses: Roche, Celgene, Janssen-Cilag, EUSA Pharma. FC \u2013 Honoraria from; Roche, Servier, Gilead. SAP - Takeda (advisory board), Kyowa Kirin (advisory board), Roche (speaker). PC - Advisory boards: AbbVie, ADC Therapeutics, Amgen, BeiGene, Celgene, Daiichi Sankyo, Gilead\/Kite, GSK, Incyte, Janssen, KyowaKirin, Nerviano Medical Science, Novartis, Roche, Sanofi, Takeda. Honoraria for lectures: AbbVie, Amgen, Celgene, Gilead\/Kite, Janssen, Novartis, Roche, Sanofi, Takeda. The other authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}